Correlation of coagulation markers and 4f-pcc-mediated reversal of rivaroxaban in a rabbit model of acute bleeding

Thrombosis Research

Volumn 135, Issue 3, 2015, Pages 554-560

  Herzog, Eva ^a   Kaspereit, Franz ^a   Krege, Wilfried ^a   Mueller Cohrs, Jochen ^a   Doerr, Baerbel ^a   Niebl, Peter ^a   Dickneite, Gerhard ^a  

^a CSL BEHRING GMBH   (Germany)

Author keywords

Animal study; Anticoagulation reversal; Haemorrhage; Prothrombin complex concentrates; Rivaroxaban

Indexed keywords

BIOLOGICAL MARKER; PROTHROMBIN COMPLEX; RIVAROXABAN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATES; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLEEDING TENDENCY; BLOOD CLOTTING; BLOOD CLOTTING TIME; CONTROLLED STUDY; HEMOSTASIS; IN VITRO STUDY; IN VIVO STUDY; INCISION; NONHUMAN; PRIORITY JOURNAL; RABBIT MODEL; ACUTE DISEASE; ANIMAL; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; HEMORRHAGE; HUMAN; METABOLISM; RABBIT;

ACUTE DISEASE; ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DISEASE MODELS, ANIMAL; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; RABBITS; RIVAROXABAN; THROMBIN;

EID: 84925759410     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.01.007     Document Type: Article

References (46)

1. R.J. Leadley Jr. Coagulation factor Xa inhibition: biological background and rationale Curr Top Med Chem 1 2001 151 159
2. E. Perzborn, J. Strassburger, A. Wilmen, J. Pohlmann, S. Roehrig, and K.H. Schlemmer In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor J Thromb Haemost 3 2005 514 521
3. A.G. Bayer Pharma Xarelto - Highlights of Prescribing Information 2014
4. W. Mueck, J. Stampfuss, D. Kubitza, and M. Becka Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban Clin Pharmacokinet 53 2014 1 16
5. E. Perzborn, S. Roehrig, A. Straub, D. Kubitza, W. Mueck, and V. Laux Rivaroxaban: a new oral factor Xa inhibitor Arterioscler Thromb Vasc Biol 30 2010 376 381
6. P.J. Molenaar, J. Dinkelaar, and A. Leyte Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation Clin Chem Lab Med 50 2012 1799 1807
7. T. Baglin, A. Hillarp, A. Tripodi, I. Elalamy, H. Buller, and W. Ageno Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis J Thromb Haemost 11 2013 756 760
8. B.A. Cotton, J.J. McCarthy, and J.B. Holcomb Acutely injured patients on dabigatran N Engl J Med 365 2011 2039 2040
9. P. Harper, L. Young, and E. Merriman Bleeding risk with dabigatran in the frail elderly N Engl J Med 366 2012 864 866
10. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
11. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, and J.L. Halperin Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
12. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, and M. Hanna Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
13. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
14. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, and J. Oldgren European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
15. S. Kaatz, P.A. Kouides, D.A. Garcia, A.C. Spyropolous, M. Crowther, and J.D. Douketis Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors Am J Hematol 87 Suppl. 1 2012 S141 S145
16. W. Ageno, A.S. Gallus, A. Wittkowsky, M. Crowther, E.M. Hylek, and G. Palareti Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e44S e88S
17. A. Fawole, H.A. Daw, and M.A. Crowther Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban Cleve Clin J Med 80 2013 443 451
18. J.H. Levy, D. Faraoni, J.L. Spring, J.D. Douketis, and C.M. Samama Managing new oral anticoagulants in the perioperative and intensive care unit setting Anesthesiology 118 2013 1466 1474
19. G. Pernod, P. Albaladejo, A. Godier, C.M. Samama, S. Susen, and Y. Gruel Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013 Arch Cardiovasc Dis 106 2013 382 393
20. C.V. Pollack Jr. Managing bleeding in anticoagulated patients in the emergency care setting J Emerg Med 45 2013 467 477
21. A.G. Turpie, R. Kreutz, J. Llau, B. Norrving, and S. Haas Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor Thromb Haemost 108 2012 876 886
22. W. Miesbach, and E. Seifried New direct oral anticoagulants - current therapeutic options and treatment recommendations for bleeding complications Thromb Haemost 108 2012 625 632
23. I. Pragst, S.H. Zeitler, B. Doerr, F.J. Kaspereit, E. Herzog, and G. Dickneite Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model J Thromb Haemost 10 2012 1841 1848
24. E. Herzog, F. Kaspereit, W. Krege, B. Doerr, J. Mueller-Cohrs, and I. Pragst Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage Anesthesiology 2014 10.1097/ALN.0000000000000520 [Epub ahead of print]
25. ® Highlights of Prescribing Information 2013
26. J.F. Lawless Statistical models and methods for lifetime data (Section 6.5.2) 1982 John Wiley & Sons New York
27. I.G. Girgis, M.R. Patel, G.R. Peters, K.T. Moore, K.W. Mahaffey, and C.C. Nessel Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF J Clin Pharmacol 54 2014 917 927
28. G. Lu, F.R. DeGuzman, S.J. Hollenbach, M.J. Karbarz, K. Abe, and G. Lee A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nat Med 19 2013 446 451
29. G. Dickneite, and M. Hoffman Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 111 2013 189 198
30. A.M. Galan, E. Arellano-Rodrigo, V. Sanz, P. Molina, J.C. Reverter, and X. Carne Reversal of the antithrombotic action of rivaroxaban and dabigatran: a clinical study in healthy volunteers Blood (ASH Annual Meeting Abstracts) 120 2012 2261
31. A. Godier, A. Miclot, B. Le Bonniec, M. Durand, A.M. Fischer, and J. Emmerich Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model Anesthesiology 116 2012 94 102
32. D. Pillitteri, A.-K. Pilgrimm-Thorp, M. Krause, T. Scholz, R. Schwerdtfeger, and T. Behrendt Antidotal effects of non-specific reversal agents on anticoagulant-induced inhibition of thrombin generation Blood (ASH Annual Meeting Abstracts) 120 2012 2273
33. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
34. M. Levi, K.T. Moore, C.F. Castillejos, D. Kubitza, S.D. Berkowitz, and S.Z. Goldhaber Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers J Thromb Haemost 12 2014 1428 1436
35. E. Perzborn, S. Heitmeier, V. Laux, and A. Buchmuller Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro Thromb Res 133 2014 671 681
36. J. Dinkelaar, P.J. Molenaar, M. Ninivaggi, B. de Laat, H.J. Brinkman, and A. Leyte In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban J Thromb Haemost 11 2013 1111 1118
37. M.K. Korber, E. Langer, S. Ziemer, E. Perzborn, C. Gericke, and C. Heymann Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study Clin Appl Thromb Hemost 20 2014 735 740
38. A. Hillarp, F. Baghaei, I. Fagerberg Blixter, K.M. Gustafsson, L. Stigendal, and M. Sten-Linder Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays J Thromb Haemost 9 2011 133 139
39. M.M. Samama, J.L. Martinoli, L. LeFlem, C. Guinet, G. Plu-Bureau, and F. Depasse Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor Thromb Haemost 103 2010 815 825
40. W. Zhou, M. Zorn, P. Nawroth, U. Butehorn, E. Perzborn, and S. Heitmeier Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban Stroke 44 2013 771 778
41. G. Escolar, V. Fernandez-Gallego, E. Arellano-Rodrigo, J. Roquer, J.C. Reverter, and V.V. Sanz Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood PLoS One 8 2013 e78696
42. H. Zahir, K.S. Brown, A. Vandell, M. Desai, J.F. Maa, and V. Dishy Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate Circulation 131 2015 82 90
43. D. Zhang, K. He, N. Raghavan, L. Wang, E.J. Crain, and B. He Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits J Thromb Thrombolysis 29 2010 70 80
44. T. Hara, A. Yokoyama, Y. Morishima, and S. Kunitada Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor Thromb Res 80 1995 99 104
45. P.C. Wong, D.J. Pinto, and R.M. Knabb Nonpeptide factor Xa inhibitors: DPC423, a highly potent and orally bioavailable pyrazole antithrombotic agent Cardiovasc Drug Rev 20 2002 137 152
46. E. Herzog, F.J. Kaspereit, W. Krege, B. Doerr, J. van Ryn, and G. Dickneite Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model Thromb Res 134 2014 729 736